Tiagabine (gabitril) experience in children

Area of Science:

• Pediatric Neurology
• Clinical Pharmacology
• Epileptology

Background:

• Tiagabine (TGB) is an established adjunctive therapy for partial seizures in adults and adolescents.
• Ongoing research explores TGB's efficacy and safety in younger pediatric populations with various epilepsy types.
• Pediatric pharmacokinetic profiles of TGB resemble those observed in adult patients.

Purpose of the Study:

• To evaluate the efficacy and safety of Tiagabine (TGB) as adjunctive therapy in pediatric patients with epilepsy.
• To assess TGB's effectiveness across different epilepsy syndromes and seizure types in children.
• To characterize the adverse event profile of TGB in pediatric populations.

Main Methods:

• An open-label, dose-escalation study in 31 US children with refractory complex partial seizures.
• A European dose-escalation study evaluating TGB (0.25-1.5 mg/kg/day) in 52 children aged 2-15 years.
• Assessment of seizure rate reduction and adverse events over treatment periods.

Main Results:

• TGB demonstrated greater efficacy in localization-related epilepsy syndromes, with a median 33% seizure rate reduction in 17/23 patients.
• Six patients achieved a ≥50% reduction in seizure rate; myoclonic seizures and spasms showed a poor response.
• The adverse effect profile was similar to adults, with most common events being CNS-related and decreasing over time. Mild to moderate events like asthenia and nervousness were reported.

Conclusions:

• Preliminary pediatric data suggest Tiagabine (TGB) is particularly effective for epilepsy characterized by partial seizures.
• Further investigation is warranted to confirm TGB's role in pediatric epilepsy treatment, especially for specific syndromes.
• TGB exhibits a manageable safety profile in children, comparable to that observed in adult populations.